# NC-6004(Nanoplatin) and Gemcitabine to Treat Pancreatic Cancer in Asia

> **NCT00910741** · PHASE1,PHASE2 · COMPLETED · sponsor: **NanoCarrier Co., Ltd.** · enrollment: 40 (actual)

## Conditions studied

- Locally Advanced and Metastatic Pancreatic Cancer

## Interventions

- **DRUG:** Nanoplatin (NC-6004) and Gemcitabine

## Key facts

- **NCT ID:** NCT00910741
- **Lead sponsor:** NanoCarrier Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-05
- **Primary completion:** 2013-07
- **Final completion:** 2013-07
- **Target enrollment:** 40 (ACTUAL)
- **Last updated:** 2014-01-09

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00910741

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00910741, "NC-6004(Nanoplatin) and Gemcitabine to Treat Pancreatic Cancer in Asia". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT00910741. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*